The Sackler Family: When $10 Billion Can't Save Your Legacy

The Sackler Family, beneath the $10 billion surface of charitable giving and cultural patronage, had their company Purdue Pharma develop marketing strategies that would revolutionize how America treated pain—and ultimately trigger one of the most devastating public health crises in the nation's history. ---------------------------- Gain FREE access to secret full-length episodes on wealthy families "too scandalous for YouTube" by joining our newsletter: https://www.substack.com/@oldmoneyluxury ---------------------------- TIMESTAMPS: 0:00 Introduction Chapter 1: The Sumptuous Sacklers Chapter 2: The Start of the Sacklers Chapter 3: The Money Flows In Chapter 4: The Controversial Crisis Chapter 5: The Legacy ---------------------------- When you think of America's great family fortunes, tales of oil barons, railroad tycoons, and industrial pioneers usually come to mind. But in the quiet corridors of academic medicine, three brothers from Brooklyn were building something different: a pharmaceutical empire that would eventually make them one of the nation's wealthiest families. Their path to riches wasn't paved with steel or oil, but with something far more subtle—the art of medical marketing and pain management. By the 1990s, the Sackler name adorned the walls of Harvard, Oxford, and the Louvre, their philanthropy establishing them among society's elite. The Sacklers amassed their fortune through their company Purdue Pharma, which developed and aggressively marketed OxyContin, a powerful opioid painkiller. Through sophisticated marketing campaigns and influential connections, they convinced the medical community that OxyContin was safe and non-addictive. Their strategy worked brilliantly—perhaps too well—as OxyContin sales skyrocketed from $48 million in 1996 to $1.1 billion by 2000. The family's wealth grew to nearly $11 billion, enabling them to become prominent philanthropists, with their name gracing prestigious museums, universities, and cultural institutions worldwide. However, as America's opioid crisis deepened, investigations revealed the family's role in downplaying addiction risks and aggressively promoting their product despite mounting evidence of abuse. In 2007, Purdue Pharma pleaded guilty to criminal charges of misbranding OxyContin, paying $600 million in fines—but this was just the beginning of their legal troubles. By 2019, facing thousands of lawsuits, Purdue Pharma declared bankruptcy and proposed a $4.5 billion settlement from the Sackler family. Cultural institutions began distancing themselves, with many removing the Sackler name from their buildings and programs. Today, the Sackler legacy stands as a cautionary tale of how the pursuit of profit can lead to catastrophic consequences when unchecked by moral responsibility. Their story reveals the dark side of American capitalism, where marketing brilliance and medical innovation intersected with devastating human cost. From their humble beginnings as immigrants in Brooklyn to their rise as pharmaceutical titans and subsequent fall from grace, the Sackler saga demonstrates how even billions of dollars can't protect a legacy tainted by controversy. In the end, their name became synonymous not with philanthropy and cultural patronage, but with America's opioid epidemic—a crisis that has claimed hundreds of thousands of lives and continues to affect communities nationwide.